Skip to content

Efficiency of unani formulation in ringworm disease

Efficacy of Unani Formulations, Irsale Alaq and Terbinafine, in Quba â?? A Comparative Randomized Controlled Clinical Trial - -

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/03/041124
Enrollment
111
Registered
2022-03-15
Start date
Unknown
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Joshanda Aftimoon orally and Tila Ushaq topically: Joshanda Aftimoon (Cuscuta reflexa Roxb.): Decoction made up of the powdered Aftimoon simmered in one glass of hot water and filtered

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ï?? Patients aged 18-60 years of either sex with a clinical diagnosis of Tinea corporis and/or Tinea cruris with ï?? Patients with Global assessment score of >= 5 with positive KOH mount ï?? Patients who will give consent and are able to do follow up

Exclusion criteria

Exclusion criteria: ï?? Immuno-compromised patients ï?? Patients with extensive Dermatophytosis, other forms of tinea infections, superadded bacterial infection ï?? Patients with contact dermatitis, atopic dermatitis, psoriasis, other skin diseases ï?? Patients with a history of hypersensitivity to allylamine antifungals ï?? Patients who received topical antifungal within 1 week and systemic antifungals within 4 weeks prior to enrolment ï?? Patients with a known history or clinical evidence of bleeding disorders, severe systemic illness and uncontrolled diabetes mellitus ï?? Pregnant and lactating females

Design outcomes

Primary

MeasureTime frame
Comparison of achieved complete clearance among groups at the end of treatmentTimepoint: Baseline and after treatment

Secondary

MeasureTime frame
a. Comparison of achieved clinical cure among groups at the end of treatment b. Comparison of achieved Mycological cure among groups at the end of treatment c. Comparison of relapse among groups at the end of treatment d. Improvement in DLQI Timepoint: before and After study

Countries

India

Contacts

Public ContactProf MA Quamri

National Institute of Unani Medicine

drmaquamri@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026